ECL delivered its July 28 earnings and the bulls were right: the stock jumped 4.2% on the day and is up 7.1% on the week to $282.90, vindicating the aggressive call-side positioning flagged in the pre-earnings note.
The analyst response to the print has been swift and broadly positive. Multiple firms lifted price targets on the morning after results, with BMO Capital the most bullish — raising its target to $360 from $345 while keeping an Outperform rating. JP Morgan moved to $305 from $295, maintaining Overweight. Mizuho nudged its target to $327 from $325. Those moves follow an Oppenheimer upgrade to Outperform on July 17 and a Deutsche Bank target raise to $335 earlier in the month. The Street's consensus target now sits at $323.62, implying roughly 14% additional upside from current levels. The direction of travel is clear: no firm downgraded, no firm cut a target post-print. The analyst recommendation differential factor ranks in the 93rd percentile versus the broader universe — one of the strongest readings in the dataset.
Options positioning has stayed decisively bullish through the event. The put/call ratio came in at 0.37 on the day of results — nearly 2.4 standard deviations below its 20-day average of 0.59, and close to the 52-week low of 0.22. The pre-earnings call loading documented in the prior note was not unwound into the print; if anything, the ratio has compressed further from mid-month levels above 0.72. That is an unusual setup — typically some options positioning normalises after a catalyst. It may reflect ongoing call buying as the stock re-rates higher, rather than residual pre-event positioning.
Short interest offers no counternarrative. Bears hold just 1.2% of the free float short — a low level that has been grinding lower for a month, down roughly 17% from late June peaks. Borrow conditions are extraordinarily loose, with availability running at nearly 8,000% of short interest. That means for every share currently borrowed short, there are roughly 80 more available in the lending pool. Cost to borrow is 0.49% — barely above benchmark — and has eased about 11% on the week despite the sharp price move. There is no structural short pressure, and no sign that this week's rally has triggered any meaningful new shorting.
The forward earnings picture is where the bulls have the clearest case. The 12-month forward EPS growth factor ranks in the 98th percentile — essentially best-in-class for upward estimate revision. The bear case — softer hospital sales, life sciences deceleration, raw material volatility — has not gone away, and the valuation remains stretched at roughly 32x trailing earnings with an EV/EBITDA near 18.5x. Quality peers moved sharply this week too: SHW added 8.3% on the day and 11.2% on the week, RPM gained 10.1%, while PPG lagged with a 2.9% weekly move. ECL's 7.1% gain lands between the leaders and the laggards — respectable, but not the top performer in its own peer group despite a clean print.
The next earnings date is October 27. Between now and then, the focus shifts to whether the analyst upgrade cycle — already strong — broadens further, and whether the forward earnings estimates that now rank in the 98th percentile continue to drift higher or begin to consolidate after the post-results target raises.
See the live data behind this article on ORTEX.
Open ECL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
